APLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Apellis Pharmaceuticals Inc (APLS) is not a strong buy at the moment given the user's long-term investment strategy and beginner level. While the stock has potential positive catalysts such as hedge fund buying and a strong revenue growth trend, the significant insider selling, declining net income, and lack of recent trading signals suggest it is better to hold off for now.
The MACD is slightly positive but contracting, RSI is neutral at 37.961, and moving averages are converging, indicating no strong trend. The stock is trading near its support level (S1: 21.861) with resistance at R1: 23.779. Overall, the technical indicators suggest a neutral stance.
Hedge funds are increasing their positions, with buying up 132.99% last quarter.
Revenue growth of 132.98% YoY in Q3
Analysts like BofA and Barclays have positive views on the stock's potential, with price targets above the current level.
Insiders are selling heavily, with a 2370.20% increase in selling over the last month.
Net income and EPS have dropped significantly YoY, indicating profitability concerns.
Wells Fargo lowered its price target due to slower-than-expected ramp-up of key products.
In Q3 2025, revenue increased significantly by 132.98% YoY to $458.58M, but net income dropped by -475.52% YoY to $215.72M. EPS also fell by -460.87% YoY to 1.66. Gross margin improved to 94.65%, up 14.10% YoY, showing operational efficiency despite profitability challenges.
Analysts are mixed but leaning positive. Barclays initiated coverage with an Equal Weight rating and a $24 price target. BofA upgraded the stock to Buy with a $28 price target, citing strong commercial potential for Empaveli. Wells Fargo lowered its target to $26 due to slower-than-expected product ramp-up but maintained an Overweight rating. Stifel also reduced its target to $48 but kept a Buy rating.
